Oculis

61 articles about Oculis

• Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market

  4/11/2024

  Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis” or the “Company”), today announced that on April 11, 2024 it completed a financing of approximately $59 million, consisting of the issuance of 5,000,000 of its ordinary shares, nominal value CHF 0.01 per share (the “Shares”) at a purchase price of $11.75 per Share.

• Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development

  4/10/2024

  Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced the appointment of Dr. Snehal Shah, executive leader with over two decades of research & development and regulatory experience, to the role of President of R&D.

• Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

  4/8/2024

  Oculis Holding AG announced that Eric Donnenfeld, M.D., presented the positive results from the Phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS Annual Meeting, which took place April 5-8, 2024, in Boston, MA.

• Oculis to Participate at Upcoming April 2024 Investor Conferences

  4/4/2024

  Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced that Oculis’s management will be attending and presenting at the following upcoming investor conferences.

• Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

  3/18/2024

  Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced fourth quarter and full year financial results for the period ended December 31, 2023, and an overview of the Company’s progress.

• Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

  2/28/2024

  Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, provides updates at its in-person and virtual R&D Day on continued progress in advancing its late-stage clinical trials and strengthening the organization with additional senior appointments to its management and advisory teams.

• Oculis to Present at Upcoming February 2024 Investor Conferences

  1/29/2024

  Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced that Oculis’ management will be attending and presenting at the following upcoming investor conferences:

• Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024

  1/22/2024

  Oculis Holding AG today announced it will host an in-person R&D Day in Midtown, New York City, on Wednesday, February 28, 2024 from 9:00 AM to 11:00 AM ET.

• Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease

  12/7/2023

  Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces First Patient First Visit (FPFV) in its Phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ innovative anti-TNFα biologic eye drop, for the treatment of Dry Eye Disease (DED).

• Oculis to Present at Upcoming November 2023 Investor Conferences

  11/8/2023

  Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer will be attending and presenting at the following upcoming investor conferences.

• Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema

  11/1/2023

  Oculis Holding AG announced that the positive results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema, will be presented as a late-breaking abstract at the American Academy of Ophthalmology 2023 Annual Meeting, taking place Friday, November 3, 2023 through Monday, November 6, 2023 in San Francisco, California.

• Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

  10/10/2023

  Oculis Holding AG announced that Professor Ramin Tadayoni, M.D., Ph.D., presented the positive results from Stage 1 of the Phase 3 DIAMOND trial of OCS-01 in patients with DME at the 23rd EURETINA congress, which took place October 5-8, 2023 in Amsterdam, the Netherlands.

• Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema

  10/5/2023

  Oculis Holding AG announced that the positive readout from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema will be presented as a late-breaking abstract at the 23rd EURETINA Congress, taking place Thursday, October 5, 2023 through Sunday, October 8, 2023 in Amsterdam, the Netherlands.

• Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase

  9/11/2023

  Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced the appointment of global commercial executive with extensive ophthalmology experience, Rebecca Weil, to the role of Chief Commercial Officer.

• Oculis to Present at Upcoming September 2023 Investor Conferences

  8/30/2023

  Oculis Holding AG announced that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer will be attending and presenting at the following upcoming investor conferences:

• Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update

  8/29/2023

  Oculis Holding AG announced second quarter and first half 2023 financial results for the period ended June 30, 2023, and an overview of the Company’s progress.

• OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery

  8/8/2023

  Oculis Holding AG announced positive top line results from its Phase 3 OPTIMIZE trial with OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical OPTIREACH® formulation of dexamethasone for the treatment of inflammation and pain following ocular surgery.

• First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema

  8/2/2023

  Oculis Holding AG announces that the first patient has been enrolled in the investigator-initiated LEOPARD trial evaluating the potential of OCS-01 eye drops, Oculis’ novel high concentration preservative-free topical OPTIREACH formulation of dexamethasone, for the treatment of cystoid macular edema.

• Oculis Announces to Present at Upcoming August Investor Conferences

  7/26/2023

  Oculis Holding AG today announced that it will participate at the following upcoming investor conferences.

• Oculis to Present at OIS Retina Innovation Summit

  7/19/2023

  Oculis Holding AG today announced that Riad Sherif, MD, CEO of Oculis, will participate at OIS Retina Innovation Summit , an event organized by Ophthalmology Innovation Source, on July 27, in Seattle, Washington.